Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
How do you approach treatment of early onset RA with minimal peripheral disease and aggressive cervical atlantoaxial involvement?
RF/CCP negative, +hand synovitis on exam
Related Questions
Are you comfortable with using NSAIDs in a patient on methotrexate for inflammatory arthritis?
How would you approach a patient with anti-scl70 ab positive sine scleroderma complicated by ILD who also has seropositive RA with active arthritis?
When considering a biologic for seropositive RA after failure of methotrexate or triple therapy, do you consider using abatacept as a first line biologic or would prefer choosing TNFi?
What is your typical steroid taper regimen for managing RA flares?
When do you recommend initiation of targeted therapies in active RA with history of malignancy?
How would you approach management of a patient with seropositive RA and UIP-ILD, with concern for active lung disease?
Would you consider using a JAK inhibitor for a patient with RA associated scleritis?
What factors would encourage you to choose abatacept vs tocilizumab in a patient with RA-ILD with a UIP pattern of pulmonary fibrosis?
Do you feel comfortable using Jak inhibitors in patients with a strong family history of CAD, but no other risk factors?
Do you have experience combining tocilizumab with mycophenolate in patients with scleroderma lung disease and inflammatory arthritis?